Gan & Lee Pharmaceuticals

Gan & Lee Pharmaceuticals USA Corporation is the U.S. subsidiary of Gan & Lee Pharmaceuticals, a China-based pharmaceutical company specializing in the development, manufacturing, and commercialization of insulin analogs and related medical devices. Founded in 1998 and headquartered in Beijing, Gan & Lee has developed a portfolio of insulin products and expanded its operations internationally, including through its U.S. presence.

The company’s U.S. operations, established in New Jersey in 2014, support global clinical development, regulatory activities, and business development. Gan & Lee has used its U.S. organization to advance clinical programs and pursue regulatory approvals for its diabetes therapies in the American market.

Gan & Lee’s research and development activities extend beyond established insulin products into longer-acting insulin formulations and other metabolic therapies. Its pipeline has included an ultra-long-acting weekly insulin candidate as well as GLP-1 receptor agonist programs being evaluated for areas such as weight management.

The company also works with international pharmaceutical partners to expand access to its therapies. Gan & Lee has entered commercialization and supply arrangements with Sandoz involving insulin analogs used in the treatment of type 1 and type 2 diabetes, supporting the company’s broader international expansion.

Through its pharmaceutical research, clinical development, manufacturing capabilities, and international operations, Gan & Lee aims to develop and provide medicines and healthcare solutions that address significant metabolic and chronic disease needs. Its U.S. organization serves as an important part of the company’s efforts to advance therapies through clinical and regulatory development and expand its presence in developed markets.